Products for Research Use Only
RegisterLogin

FHD-609

CAT: 0804-HY-153367-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-153367-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
FHD-609 is a PROTAC degrader and inhibitor of BRD9 (Bromodomain-containing protein 9). FHD-609 targets to ncBAF, can be used for research of wide range of cancers that contain a mutation in a BAF complex subunit. FHD-609 in combination with Telomelysin or INO5401, may play a role in adrenocortical carcinoma (ACC) treatment. (Blue: BRD9 ligand-6 , Black: linker (HY-168309) ; Pink: (S) -Deoxy-thalidomide-Br (HY-168308) )[2][3][4][5].
CAS Number
2676211-64-4
UNSPSC
12352005
Target
Epigenetic Reader Domain; PROTACs
Type
Reference compound
Related Pathways
Epigenetics; PROTAC
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/fhd-609.html
Purity
99.15
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
COC1=C(CN2CCC(CN3CCC4(CN(C5=CC(C(N([C@@H]6C(NC(CC6)=O)=O)C7)=O)=C7C=C5)C4)CC3)CC2)C(OC)=CC(C(C8=C9C=NC(N%10CCC%10)=C8)=CN(C)C9=O)=C1
Molecular Formula
C47H56N8O6
Molecular Weight
829.00
References & Citations
[1]Rechberger JS, et al. Atypical teratoid rhabdoid tumor (ATRT) : disease mechanisms and potential drug targets. Expert Opin Ther Targets. 2022 Mar;26 (3) :187-192. |[2]Hescheler DA, et al. Targeted Therapy for Adrenocortical Carcinoma: A Genomic-Based Search for Available and Emerging Options. Cancers (Basel) . 2022 May 31;14 (11) :2721. |[3]Lin M, et al. Long acting injectable FHD-609 micro-suspension: A potent BRD9 degrader with comparable efficacy, reduced frequency of dosing in preclinical models[J]. Cancer Research, 2024, 84 (6_Supplement) : 7185-7185.|[4]Collins M, et al. Preclinical validation of target engagement assays and investigation of mechanistic impacts of FHD-609, a clinical-stage BRD9 degrader being developed for the treatment of synovial sarcoma[J]. strategies, 2022, 36: 936-950.|[5]Liu X, et al. PROTACs in Epigenetic Cancer Therapy: Current Status and Future Opportunities. Molecules. 2023 Jan 26;28 (3) :1217.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 1
Isoform
BRD9

Related Products

CatalogName
HY-114724HSR-609
HY-19805-01STO-609
HY-19805ASTO-609 (acetate)
HY-W952711CRBN ligand-609
HY-R01864A-01Hsa-miR-609 agomir
HY-RI01864A-01Hsa-miR-609 antagomir
HY-R01864-01Hsa-miR-609 mimic
HY-RI01864-01Hsa-miR-609 inhibitor
HY-160210-01BAY-6096
HY-R01865-01Hsa-miR-6090 mimic

Alternative Products

CatalogName
C01914-1gFHD-609
A23943-10FHD-609 10mg
A23943-100FHD-609 100mg
A23943-50FHD-609 50mg
A23943-5FHD-609 5mg
GTR19166786-01FHD-286

Popular Products